Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with standard chemotherapy before surgery had improved long term survival compared to those who received chemotherapy alone, at 5 years after completing treatment. Prof. Patrick Forde of … Read more
Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer than the same targeted therapy by itself, according to researchers from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine’s Abramson Cancer … Read more
TOPLINE: Among Medicare beneficiaries with advanced cancer, 45% had more than one acute care visit, in-hospital mortality, late receipt of systemic therapy, or hospice entry in the last 30 days of life. METHODOLOGY: Historical evidence has shown that patients with advanced cancer often receive potentially aggressive care at the end of life, including late initiation … Read more
A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies. The research, published in Clinical Cancer Research, found that measuring the interaction between two proteins, RAS and RAF, could provide valuable insights into the effectiveness of treatments for patients … Read more